BIOMAT Database Logo BIOMAT Database Logo

TSH-binding inhibitor immunoglobulin (TBII) in thyroidal venous blood and histological grade of intrathyroidal lymphocyte appearance in Graves' disease. 1989

Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

The aim of this study is to investigate the possibility of determining the appropriate amount of thyroid tissue to leave behind as remnant weight in subtotal thyroidectomy for Graves' disease by measuring the TBII value, and correlating the outcome to the grade of intrathyroidal lymphocyte infiltration. We therefore have investigated the levels of TBII in the thyroidal (T-TBII) and peripheral (P-TBII) venous blood, and the grade of lymphocytic infiltration and lymph follicle formation in the intrathyroidal tissue. There was no parallel relationship between the T-TBII value and the grade of lymphocytic infiltration and lymph follicle formation. There was no marked difference between the T-TBII value and the P-TBII value. It was thus not possible to use these data to determine the proper remnant weight of Graves' thyroid tissue at the time of surgery.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
[Determination of TSH binding inhibitor immunoglobulin (TBII) with a TSH radioreceptor assay kit (Smith)].
September 1983, Kaku igaku. The Japanese journal of nuclear medicine,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
[Clinical usefulness of the assay of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease: Effect of antithyroid drug treatment on TBII and prognosis].
December 1983, Kaku igaku. The Japanese journal of nuclear medicine,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
[Studies on the radioreceptor assay of TSH: the properties of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease (author's transl)].
October 1979, Nihon Naibunpi Gakkai zasshi,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Possible binding site of thyrotropin binding inhibitor immunoglobulin (TBII) on the thyrotropin (TSH) receptor, which is different from TSH binding site.
October 1990, Biochemical and biophysical research communications,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Interaction between thyrotropin (TSH) binding inhibitor immunoglobulins (TBII) and soluble TSH receptors in fat cells.
April 1981, The Journal of clinical endocrinology and metabolism,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin.
February 1994, Clinical endocrinology,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Changes in thyrotropin binding inhibitor immunoglobulin (TBII) concentration before and after various treatments in a patient with infiltrative Graves' ophthalmopathy.
April 1985, Endocrinologia japonica,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor.
August 2002, Clinical endocrinology,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
Demonstration of anti-TSH antibody in TSH binding inhibitory immunoglobulin-positive sera of patients with Graves' disease.
March 2002, Clinical endocrinology,
Y Kasuga, and A Sugenoya, and S Kobayashi, and H Masuda, and M Fujimori, and F Iida
[Effect of carbimazole and dexamethasone on the TSH bond (TBII) inhibiting immunoglobulins in Graves-Basedow disease].
November 1988, Revista clinica espanola,
Copied contents to your clipboard!